

Colin Neil Edelman, Esquire,  
 Stephen John Sauvain, Esquire,  
 Simeon Andrew Maskrey, Esquire,  
 The Honourable Launcelot Dinadan James Henderson,  
 Michael Jonathan Black, Esquire,  
 Andrew George Lindsay Nicol, Esquire,  
 John Yeoman Randall, Esquire,  
 Edward Hamilton Fitzgerald, Esquire,  
 Christopher Thomas Storey, Esquire,  
 Michael John Powers, Esquire,  
 Miss Catherine Mary Newman,  
 Miss Anna Evelyn Hamilton Pauffley,  
 Jonathan Nicholas Crispin Gaisman, Esquire, and  
 Richard David Adkins, Esquire.

to be Her Majesty's Counsel learned in the Law.  
 (10 SI)

C. I. P. Denyer

relevant section of the Act or that any requirement of that Act or any Instrument made under it has not been complied with, may, within 6 weeks of 28th April 1995, apply to the High Court for this purpose.

A copy of the Order and map may be inspected during normal office hours at the offices of Gwent County Council, County Hall, Cwmbran, Gwent. (566)

The following notice is in substitution for that which appeared on page 3956 of The London Gazette dated 14th March 1995:

## DEPARTMENT OF TRADE AND INDUSTRY

### INSURANCE COMPANIES ACT 1982

#### Notice of direction under section 11

Notice is hereby given, pursuant to section 12(8) of the Insurance Companies Act ("the Act") that on 7th March 1995, the Secretary of State gave a direction under section 11 of the Act to AFLAC INSURANCE COMPANY LIMITED. The direction provided that the Company shall cease to be authorised to effect contracts of insurance in the United Kingdom and was given at the request of the Company.

Department of Trade and Industry

## THE WELSH OFFICE Y SWYDDFA GYMREIG

### The A4042 Trunk Road (Mamhilad, Gwent) (Prohibition of U-Turns and Right Hand Turn) Order 1995

Notice is hereby given that on 24th April 1995, the Secretary of State made the above Order which will come into operation on 2nd May 1995.

The effect is as stated in Notice 573 in *The London Gazette* No. 53965 dated 24th February 1995.

Anyone wishing to question the validity of the Order or of any of its provisions on the grounds that it is not within the powers of the

## DEPARTMENT OF HEALTH MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 0171-273 0422 or 0425

### Product Licences Authorised

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
00003/0352	The Wellcome Foundation Limited	Valtrex Tablets 500 mg	Valaciclovir HSE 500.0 mg	For the treatment of Herpes Zoster (Shingles). Prescription Only Medicine See PL/00003/0352.	20th January 1995
00003/0353	The Wellcome Foundation Limited	Valtrex Tablets 1 g	Valaciclovir HSE 1,000.0 mg		20th January 1995
00003/0356	The Wellcome Foundation Limited	Retrovir Tablets 200 mg	Zidovudine 1 HSE 200 mg	For the management of patients with advanced HIV disease, such as those with the Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC). In adult patients with HIV infection, Retrovir oral formulations are also indicated in early symptomatic patients with CD4 counts of less than 500/mm <sup>3</sup> or in asymptomatic patients with markers indicating risk of progressive disease including repeated CD4 counts falling less than 200/mm <sup>3</sup> , or with CD4 counts between 500/mm <sup>3</sup> and 200/mm <sup>3</sup> which are rapidly falling. Retrovir is also indicated for HIV-Infected children over the age of 3 months who have HIV-Related symptoms or who are asymptomatic with markers indicating significant HIV-Related Immune Suppression. Prescription Only Medicine See PL/00003/0356.	24th January 1995
00003/0357	The Wellcome Foundation Limited	Retrovir Tablets 300 mg	Zidovudine 1 HSE 300 mg		24th January 1995
00006/0312	Lilly Industries Limited (1/4 Eli Lilly and Company Limited, Dista Products Limited and Greenfield Pharmaceuticals)	Humulin M5 Cartridge—100 iu/ml Injection	Soluble Human Insulin (PRB) EP 50 iu Isophane Human Insulin (PRB) EP 50 iu	For the treatment of patients with Diabetes Mellitus who require insulin for the maintenance of Glucose Homeostasis. It is also indicated for the initial control of Diabetes Mellitus and Diabetes Mellitus in pregnancy. Pharmacy Medicine	24th January 1995
0011/0203	John Wyeth and Brother Limited (1/4 Wyeth Laboratories)	Premelle 5	Medroxyprogesterone Acetate EP 5.0 mg Conjugated Oestrogens USP 14.6 mg Desiccation at 4.29%	Treatment of the following conditions in women with an intact uterus. 1. Vasomotor symptoms associated with oestrogen deficiency. 2. Atrophic Vaginitis. 3. Atrophic Urethritis. 4. Prevention and management of Osteoporosis associated with oestrogen deficiency, in women at risk of developing fractures. Prescription Only Medicine	10th January 1995